Inovio Pharmaceuticals

Inovio launches Zika vaccine trial to explore early signals

Monday, August 29, 2016

Inovio Pharmaceuticals has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study’s placebo control design to provide exploratory signals of vaccine efficacy.

[Read More]

Inovio, NIH, Mayo to initiate hepatitis C immunotherapy trial

Thursday, April 28, 2016

Inovio Pharmaceuticals has announced that its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HCV) treatments. The study will enroll patients who are in the early stages of chronic HCV infection to determine the therapy’s ability to decrease and potentially eliminate HCV viral load, measure HCV specific immune responses and durability of these immune responses, and evaluate safety and tolerability. In this dose-escalation study INO-8000 will be combined with increasing doses of DNA-based IL-12 (INO-9012), an immune activator, which in previous studies has been shown to increase the therapeutic immune response to DNA immunotherapies.

[Read More]

Inovio receives $24M DARPA grant

Wednesday, September 23, 2015

Inovio Pharmaceuticals has announced that the U.S. Defense Advanced Research Projects Agency (DARPA) has exercised its option to provide an additional $24 million to support the Inovio-led development of multiple treatment and prevention approaches against Ebola. The option exercise, part of the $45 million Ebola program grant announced in April when Inovio received an initial $21 million award, was contingent upon Inovio successfully leading the completion of certain preclinical and clinical development milestones.

[Read More]

Inovio Pharmaceuticals, MedImmune, University of Pennsylvania partner

Wednesday, October 22, 2014

The Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of PennsylvaniaInovio Pharmaceuticals and MedImmune, the global biologics R&D arm of AstraZeneca. The group will develop DNA-based monoclonal antibodies (mAbs) for infectious disease treatment. DARPA is an agency of the U.S. Department of Defense that creates and supports novel technologies important for national security.

[Read More]

Inovio Pharmaceuticals acquires DNA therapies from University of Pennsylvania

Wednesday, May 21, 2014

Inovio Pharmaceuticals has acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer’s disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University‘s Shanghai Medical College, who worked closely with Dr. David Weiner at the University of Pennsylvania. Inovio will make clinical and regulatory milestone payments to the University.

[Read More]